Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors

Oral administration provides a simple and non-invasive approach for drug delivery. However, due to poor absorption and swift enzymatic degradation in the gastrointestinal tract, a wide range of molecules must be parenterally injected to attain required doses and pharmacokinetics. Here we present an...

Full description

Bibliographic Details
Main Authors: Abramson, Alex (Author), Frederiksen, Morten Revsgaard (Author), Vegge, Andreas (Author), Jensen, Brian (Author), Poulsen, Mette (Author), Mouridsen, Brian (Author), Jespersen, Mikkel Oliver (Author), Kirk, Rikke Kaae (Author), Windum, Jesper (Author), Hubálek, František (Author), Water, Jorrit J (Author), Fels, Johannes (Author), Gunnarsson, Stefán B (Author), Bohr, Adam (Author), Straarup, Ellen Marie (Author), Ley, Mikkel Wennemoes Hvitfeld (Author), Lu, Xiaoya (Author), Wainer, Jacob (Author), Collins, Joy (Author), Tamang, Siddartha (Author), Ishida, Keiko (Author), Hayward, Alison (Author), Herskind, Peter (Author), Buckley, Stephen T (Author), Roxhed, Niclas (Author), Langer, Robert (Author), Rahbek, Ulrik (Author), Traverso, Giovanni (Author)
Format: Article
Language:English
Published: Springer Science and Business Media LLC, 2022-03-29T18:45:57Z.
Subjects:
Online Access:Get fulltext
Description
Summary:Oral administration provides a simple and non-invasive approach for drug delivery. However, due to poor absorption and swift enzymatic degradation in the gastrointestinal tract, a wide range of molecules must be parenterally injected to attain required doses and pharmacokinetics. Here we present an orally dosed liquid auto-injector capable of delivering up to 4-mg doses of a bioavailable drug with the rapid pharmacokinetics of an injection, reaching an absolute bioavailability of up to 80% and a maximum plasma drug concentration within 30 min after dosing. This approach improves dosing efficiencies and pharmacokinetics an order of magnitude over our previously designed injector capsules and up to two orders of magnitude over clinically available and preclinical chemical permeation enhancement technologies. We administered the capsules to swine for delivery of clinically relevant doses of four commonly injected medications, including adalimumab, a GLP-1 analog, recombinant human insulin and epinephrine. These multi-day dosing experiments and oral administration in awake animal models support the translational potential of the system.